2019 Clinical Trials DEA Policy 
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
NORML
JANUARY 17, 2019
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. . The agency ultimately rejected her decision.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 12, 2019), [link] [ [link] ]. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al.,
SpeedWeed
MARCH 5, 2021
Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Rescheduling cannabis will not necessarily facilitate clinical research.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. For two decades, U.S.
Expert insights. Personalized for you.
103 
Let's personalize your content